Validation of an Adjusted Dosing Algorithm of Carboplatin
Status:
Unknown status
Trial end date:
2015-12-01
Target enrollment:
Participant gender:
Summary
An adjusted dosing algorithm for the dosing of the anticancer drug carboplatin has been
developed, that accounts for high BMI, low serum creatinine values and maximal calculated
renal function. The hypothesis is that this new dosing algorithm provides a more accurate and
safe dose than dosing according to the old standard of care.